Our Mission
Our Story
Search
Our Work with the Gates Foundation | COVID-19 | Boehringer Ingelheim US
With global life science companies, we are joining the COVID-19 Therapeutics Accelerator of the Bill & Melinda Gates Foundation to fight the pandemic.
Ensuring Global Access to Corona Care | Boehringer Ingelheim US
BI has signed a communiqué with the Bill & Melinda Gates Foundation and 15 other companies committing to provide access to COVID-19 related services.
BI Cares Financial Contributions Program: Strengthening Communities
BI Cares Financial Contributions Program: Strengthening Communities
Oncology & Cancer Immunology
Oncology & Cancer Immunology
First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes
First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes
Cooking Up Change: Boehringer Cares Foundation and World Central Kitchen’s Recipe for Fighting Hunger
Our Boehringer Cares team has partnered with World Central Kitchen who aim to address the critical issue of global food insecurity.
Oncology & Cancer Immunology
Oncology & Cancer Immunology
New affordability initiative with GoodRx for our biosimilar
Boehringer Ingelheim announces patient affordability initiative with GoodRx for biosimilar
BI initiates Study of Sequencing in EGFR Lung Cancer | BI US
Boehringer Ingelheim has initiated a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive advanced NSCLC.
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
Fighting Rabies in Madagascar | Boehringer Ingelheim US
Find out more about the Boehringer Ingelheim efforts to fight Rabies in Madagascar. Hear from a veterinarian who administered 75,000 vaccines to cats & dogs on the island.
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Focus on Alliance Management
Focus on Alliance Management
Koropi
With its presence in Greece of more than a half century, Boehringer Ingelheim inaugurated the production facility in Koropi in 1975.
Targeting HER2 in cancer
Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.
Accountability, Agility, Intrapreneurship
How we work together
FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US
FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.
Sant Cugat del Vallès (Barcelona)
Boehringer Ingelheim settled in Spain in 1952. For almost 70 years, t
The View from Both Sides of the Table
The View from Both Sides of the Table
BI & Eli Lilly & Co. Update for TRADJENTA® & JENTADUETO® | Boehringer Ingelheim US
Read about the approved updates to the PI for Tradjenta® (linagliptin) tablets and Jentadueto® (linagliptin & metformin HCI). View ISI, PI and Med Guide.
Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month
Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.
Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.
Recognized as an inclusive workplace for the fifth time
Recognized as an Inclusive Workplace for the Fifth Time